QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...

QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB On World TB Day, milestone confirms blood test as gold standard in global fight against the disease Accurate testing can ...

QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology ...

Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United ...

QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, receives Chinese NMPA approval as test for active tuberculosis detection World Health ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis ...

New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin ...

Here are three things to know. The Quantiferon-TB Gold Plus test is designed to detect latent tuberculosis in patients. The blood test offers a broad look into an individual’s immune response to ...

Venlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- QIAGEN (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay.

Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk ...